Dynorphin opioids are a family of multiple structurally oocytes expressing recombinant heteromeric NMDA receptors related peptides that derive from a common precursor, proand in cultured hippocampal neurons with the use of voltage-dynorphin ( Kakidani et al. 1982 ) . Dynorphin A, a 17-clamp techniques. At an extracellular added glycine concentra-amino-acid peptide, was first isolated from the porcine pitution of 100 nM, dynorphin A ( 1 -13 ) ( 10 mM ) greatly increased itary ( Goldstein et al. 1979 ) and has been found in several the amplitude of NMDA-activated currents for all heteromeric locations in the spinal cord and brain: in laminae I and V subunit combinations tested; on average, the potentiation was:
of the dorsal horn ( Cruz and Basbaum 1985 ) , where it e1 /z 1, 3,377 { 1,416% ( mean { SE ) ; e2/ z1, 1,897 { 893%; can be released in response to high-frequency stimulation e3 /z 1, 4,356 { 846%; and e4/z 1, 1,783 { 503%. Potentiation of NMDA-activated current by dynorphin A ( 1 -13 ) was concen- ( Hutchison et al. 1990 ) ; in the periaqueductal limbic systration dependent between 0.1 and 10 mM dynorphin A ( 1 -13 ) , tem and the thalamus ( Millan et al. 1984; with a half-maximal concentration value of 2.77 mM and an 1982 ) ; in the adenohypophysis ( Seizinger 1984 ) ; in denapparent Hill coefficient of 2.53, for e2 /z1 subunits at 100 nM tate granule cells; and throughout the hippocampus added extracellular glycine. Percentage potentiation by dynor- ( McGinty et al. 1983 ) . High concentrations of immunorephin A ( 1 -13 ) was maximal at the lowest glycine concentrations active dynorphin A have been demonstrated in the hippotested ( 0.01 and 0.1 mM ) , and decreased with increasing glycine campal mossy fiber pathway ( McGinty et al. 1983 ; McLean concentration. No significant potentiation was observed at glyet al. 1987 ) , and dynorphin A was reported to be released cine concentrations ú0.1 mM for e1 /z 1, e2/ z1, and e4 /z 1 subfrom mossy fibers on stimulation of that pathway ( Chavkin units, or at ú1 mM for e3 /z 1 subunits. Potentiation of NMDAet al. 1983; Wagner et al. 1991 ) and coreleased with glutaactivated currents by dynorphin A ( 1 -13 ) was not inhibited by 1 mM of the k-opioid receptor antagonist nor-binaltorphimine, mate ( Terrian et al. 1989 ) .
and potentiation was not observed with 10 mM of the k-opioid
As ligands of the k-opioid receptors, the endogenous dyreceptor agonist trans-3,4-dichloro-N-methyl-N-[ 2-( 1-pyrroli-norphin A(1-17) (Weisskopf et al. 1993 ) and the synthetic dinyl ) -cyclohexyl ] benzene-acetamide. Potentiation of NMDA-dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (Caudle and Isaac 1988; Chavkin et al. activated current by dynorphin A ( 1 -13 ) was inhibited by the 1982) exert many of their effects via interaction with the k 1 glycine antagonist kynurenic acid ( 50 mM ) . NMDA-activated or k 2 opioid receptors. But dynorphin A(1-17) (Bakshi and current was also potentiated at low glycine concentrations by 10 Faden 1990; Henriksen et al. 1982 ) and dynorphin A(1-mM dynorphin A ( 2 -13 ) or ( 3 -13 ) , both of which have a gly-13) (Skilling et al. 1992 ) also have nonopioid activity. It cine as the first amino acid, but not by 10 mM dynorphin A ( 4 -has been suggested that some of the actions of dynorphin 13 ) , which does not have glycine as an amino acid. In hippocam-A(1-17) (Dubner and Ruda 1992; Henriksen et al. 1982;  pal neurons, 10 mM dynorphin A ( 1 -13 ) or ( 2 -13 ) potentiated steady-state NMDA-activated current in the absence of added Walker et al. 1982; Weisskopf et al. 1993 ) and dynorphin extracellular glycine. The extracellular free glycine concentra-A(1-13) (Caudle and Isaac 1988) in the nervous system tion, determined by high-performance liquid chromatography, involve modulation of the N-methyl-D-aspartate (NMDA) was between 26 and 36 nM for the bathing solution in presence subtype of glutamate receptors. Of these, inhibitory effects or absence of 10 mM dynorphin A( 1-13) , ( 2-13) , (3 -13), or of dynorphin A(1-17) on NMDA receptors involve either ( 4 -13 ) , and did not differ significantly among these solutions. the k-opioid receptor, as with the inhibition of mossy fiber The observations are consistent with the potentiation of NMDA-synaptic responses (Weisskopf et al. 1993 ) and of NMDAactivated current at low extracellular glycine concentrations re-mediated synaptic currents in CA3 pyramidal cells (Caudle sulting from an interaction of the glycine amino acids in dynoret al. 1994), or a direct action on the NMDA receptor by phin A ( 1 -13 ) with the glycine coagonist site on the NMDA dynorphin A(1-17) (Chen et al. 1995) or dynorphin A(1-receptor. Because dynorphin A is an endogenous peptide that 13) (Massardier and Hunt 1989) . In vivo, potentiating efcan be coreleased with glutamate at glutamatergic synapses, the potentiation of NMDA receptor-mediated responses could be an fects of dynorphin A on apparently NMDA receptor-medi-analog. The cRNA combinations e1/z1, e2/z1, e3/z1, or e4/z1 ated processes are, with a few exceptions (Moises and (Skilling et al. 1992; Stevens et al. 1987) ments, Sarasota, FL) . Mature Xenopus laevis frogs were anesthecauses neurotoxicity, which results in hindlimb paralysis, tized by immersion in water containing 3-aminobenzoic acid ethyl and intracerebroventricular injection of dynorphin A(1-13) ester (2 g/l). Oocytes were excised and mechanically isolated into produces motor dysfunction, such as wild running and pop-clusters of four to five oocytes, which were shaken in a water bath corn jumping (Shukla et al. 1992) ; these phenomena are in two changes of 0.2% collagenase A (Sigma, St. Louis, MO) in prevented or reversed by treatment with NMDA receptor a calcium-free bathing solution containing (in mM) 83 NaCl, 2 KCl, 1 MgCl 2 , and 5 4-(2-hydroxyethyl)-1-piperazineethanesulantagonists (Shukla et al. 1992; Skilling et al. 1992) , sugfonic acid (HEPES), pH 7.5, for l h each, to remove the connective gesting that the action of dynorphin A(1-17) and dynorphin tissue and follicular layer. After injection with cRNA, oocytes were A(1-13) involves NMDA receptor-mediated responses. In incubated for 2 days in modified Barth's saline (composition, in contrast to these in vivo observations of potentiation of mM: 83 NaCl, 2 KCl, 1 MgCl 2 , 2 CaCl 2 , and 5 HEPES) containing NMDA receptor-mediated effects, cellular electrophysiolog-sodium pyruvate (2 mM), penicillin (10,000 U/l), streptomycin ical studies have found mainly inhibitory effects of dynor-(10 mg/l), gentamycin (50 mg/l), and theophylline (0.5 mM), phin A. For example, dynorphin A(1-13) and dynorphin all from Sigma. A(2-13) were shown to depress spontaneous and glutamate-induced firing in single hippocampal CA1 and CA3 Electrophysiology of oocytes neurons (Walker et al. 1982) . In addition, NMDA-activated currents were inhibited by dynorphin A(1-13), (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , For electrophysiological recordings, oocytes were placed in a recording chamber (solution volume Ç 100 ml) and constantly and (1-32) in trigeminal neurons (Chen et al. 1995) ; by superfused with bathing medium (composition, in mM: 95 NaCl, dynorphin A(1-17) in neurons from rat spinal dorsal horn 2 KCl, 2 BaCl 2 , and 5 HEPES, pH adjusted to 7.5 with NaOH) (Cerne et al. 1994) (Caudle et al. 1994) . tion. For this work we used the synthetic, truncated dynorpocampal glia in 35-mm dishes in medium containing 90% miniphin A(1-13), which constitutes the physiologically active mal essential medium (GIBCO BRL), 10% heat-inactivated equine part of dynorphin A(1-17) (Goldstein et al. 1979) , to en-serum (HyClone, Logan, UT), 1 mM sodium pyruvate, and sure continuity with our previous study (Brauneis et al. 0.004% DNase I (Boehringer Mannheim, Indianapolis, IN). After 1996b). The observations show that dynorphin A(1-13) Ç4 h, and subsequently once weekly, one-half of the medium was can potentiate NMDA receptor-mediated responses at low removed and replaced with maintenance medium consisting of extracellular glycine concentrations. Some of these results minimal essential medium, 1 mM sodium pyruvate (Sigma), and N2 serum supplement (GIBCO BRL). Neurons were cultured for have been reported previously in preliminary form (Brauneis 1-4 wk before use in experiments. et al. 1995, 1996a) .
Electrophysiology of hippocampal neurons M E T H O D S
Patch-clamp recording of whole cell currents was performed in
Molecular biology and oocyte expression
hippocampal neurons at 20-25ЊC with the use of an Axopatch 200 patch-clamp amplifier (Axon Instruments). Patch pipettes with tip Mouse NMDA receptor subunit cDNA clones z1, e1, e2, e3, and e4 were provided by Dr. Masayoshi Mishina, Niigata University, resistances of 2-5 MV were used; series resistances of 3-10 MV were compensated by 80%. All recordings were performed in neuNiigata, Japan. Subunit-specific cRNAs were synthesized from the corresponding cDNAs in vitro from linearized templates with the rons voltage clamped at 050 mV. Solutions of NMDA and peptides were applied to neurons by gravity flow with the use of a linear use of T3 RNA polymerase in the presence of 7-methyl-G cap multibarrel array (diameter of each pipette Ç300 mm) placed Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism in accordance with the National within 100 mm of the cell body to allow for rapid solution changes. Cells were constantly superfused by extracellular medium flowing Institutes of Health Guidelines (protocol numbers LMCN-SP-01 and -05). from one pipette barrel (flow rate Ç3 ml/s), and solutions were applied by opening a valve and moving the barrel array so that the desired solution bathed the cell. Solutions of NMDA and peptides R E S U L T S were applied at intervals of ¢90 s to allow for full recovery from desensitization. The extracellular solution used in these experi-Effect of dynorphin A(1-13) on NMDA-activated currents ments contained (in mM) 150 NaCl, 5 KCl, 1 CaCl 2 , 10 HEPES, at low glycine concentrations 10 glucose, and 0.0002 tetrodotoxin, pH adjusted to 7.4 with NaOH, osmolality adjusted to 340 mosmol/kg with sucrose. The Figure 1 illustrates the effect of 10 mM dynorphin A(1-patch pipette (internal) solution contained (in mM) 140 CsCl, 13) on NMDA-activated currents in Xenopus oocytes ex-2 Mg 4 ATP, 10 bis-(o-aminophenoxy)-N,N,N,N-tetraacetic acid, pressing recombinant NMDA receptors at low extracellular and 10 HEPES, pH adjusted to 7.4 with CsOH, osmolality adjusted glycine concentrations. In the presence of 100 nM added to 310 mosmol/kg with sucrose. Solutions were prepared fresh glycine, 100 mM NMDA elicited little current in oocytes daily.
expressing e1/z1, e2/z1, e3/z1, or e4/z1 subunits, as previously reported for glycine effects on glutamate-activated Data analysis currents for recombinant NMDA receptors (Ikeda et al. Statistical analysis of concentration-response data was per-1994; Kutsuwada et al. 1992 ). The addition of 10 mM dynorformed with the use of the nonlinear curve-fitting program ALLFIT phin A(1-13) to the NMDA-containing bathing solution (DeLean et al. 1978) . Data were fitted to the logistic equation increased the amplitude of NMDA-activated currents for
each subunit combination by the following percentages: e1/ z1, 3,377 { 1,416% (mean { SE, n Å 13); e2/z1, 1,897 { where x and y are concentration and response, respectively; E max 893% (n Å 5); e3/z1, 4,356 { 846% (n Å 12); e4/z1, and E min are the maximal and minimal responses, respectively; 1,783 { 503% (n Å 14; P õ 0.05, paired t-test). The potenti-EC 50 is the half-maximal concentration; and n is the slope factor ation of NMDA-activated current by dynorphin A(1-13) ( tide, we determined the effect of 10 mM dynorphin A(1-Free glycine measurements L-Methionine sulphone (30 ml of 0.5 mg in 0.1 M HCl, Sigma) was mixed with 100 ml of the solution to be tested or 100 ml of a standard solution (containing 1.0 mg/ml glycine) in a borosilicate glass culture tube (prewashed with 6 M HCl) and dried under nitrogen at 35ЊC (Multivap, Organomation Associates, Berlin, MA). The acid residue was neutralized with 10 ml of a drying solution, as described in the Waters' High-Performance Liquid Chromatography (HPLC) Operating Manual for PICO-TAG Amino Acid Analysis System (Manual #88140, Revision 4, Waters, Milford, MA). The samples were redried under nitrogen at 35ЊC. The samples were then derivatized and analyzed by HPLC with ultraviolet detection at 254 nm as described (Cohen et al. 1986) , except that after derivatization excess reagent was removed by drying under nitrogen at 35ЊC for 60-80 min, and the residue was reconstituted in 27 ml PICO-TAG Diluent (Waters #88119) and 12 ml were injected. The Waters HPLC system consisted of two 510 pumps, Automated Gradient Controller Model 680, Temperature Control Module, Model 440 Absorbance Detector, and Rainin Mac Integrator II (Rainin, Woburn, MA). The HPLC conditions and quantification were as described for ''Analysis of physiological samples for free amino acids'' in the Waters PICO-TAG manual.
Sources of drugs and chemicals
NMDA, glycine, and dynorphin A(2-13) were purchased from Sigma; dynorphin A(1-13), (1) (2) (3) (4) (5) (6) (7) (8) , (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , and (1-32) were A(3-13) and (4-13) were custom synthesized by Peninsula Labo-Traces of representative currents, activated by 100 mM NMDA in presence ratories; kynurenic acid, nor-binaltorphimine (NorBN1), and of 100 nM added glycine for oocytes expressing e1/z1, e2/z1, e3/z1, or trans -3,4 -dichloro -N -methyl -N-[ 2 -( 1 -pyrrolidinyl ) -cyclo-e4/z1 NMDA receptor subunits, as labeled. For each set, left traces are hexyl]benzene-acetamide (U50488) were purchased from Re-control currents, middle traces show effect of 10 mM dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) search Biochemicals International (Natick, MA).
on NMDA-activated currents, and right traces are recovery Ç5 min after application of dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) -8) and , on NMDA-cated. As can be seen, the potentiation of NMDA-activated activated current in the presence of 100 nM added glycine in current by dynorphin A(1-13) was concentration dependent oocytes expressing e4/z1 subunits. Percentage potentiations between 0.1 and 10 mM dynorphin. The E max of this concen-(mean { SE) for these peptides were, respectively, 857 { tration-response curve was 2,107% potentiation, the EC 50 402% (n Å 11), 1,150 { 424% (n Å 11), and 1,003 { was 2.77 mM, and the apparent Hill coefficient was 2.53. 360% (n Å 10), with a control for dynorphin A(1-13) of 1,083 { 415% (n Å 11). Effect of glycine concentration on dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) potentiation of NMDA-activated current Concentration-response for dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) potentiation of NMDA-activated current Figure 3A shows the percentage potentiation of NMDA- Figure 2A shows traces of currents activated by 100 mM activated current by dynorphin A(1-13) plotted as a func-NMDA in the presence of 100 nM added glycine and at the tion of added glycine concentration for the heteromeric dynorphin A(1-13) concentrations indicated, recorded from NMDA subunit combinations. Fitting the data to the logistic an oocyte expressing e2/z1 subunits. Note that NMDA acti-equation yielded the following respective E max values: e1/ vated little current at dynorphin concentrations of 0.01, 0.1, z1, 2,697%; e2/z1, 1,927%; e3/z1, 3,737%; and e4/z1, and 1 mM, whereas NMDA activated increasingly larger 1,411%. For all subunit combinations, 10 mM dynorphin currents when dynorphin concentration was increased from A(1-13) potentiated NMDA-activated current significantly 3 to 30 mM. Figure 2B is the average concentration-response at added glycine concentrations of 10 and 100 nM, and at curve for dynorphin potentiation of NMDA-activated current an added glycine concentration of 1 mM as well for e3/z1 for oocytes expressing e2/z1 subunits. Each point represents (P õ 0.05, ANOVA). As the glycine concentration was the average percentage potentiation (mean { SE) of current increased, the dynorphin potentiation of NMDA-activated activated by 100 mM NMDA in the presence of 100 nM current decreased. The fitted curves indicate that the magniglycine and at the dynorphin A(1-13) concentrations indi-tude of the dynorphin potentiation decreased by half at the following glycine concentrations: e1/z1, 0.24 mM; e2/z1, 2 mM; e3/z1, 0.47 mM; and e4/z1, 0.93 mM. Dynorphin A(1-13), in the absence of NMDA, did not activate detectable current, but a dynorphin-induced potentiation of NMDA-activated current was observed in the absence of added glycine [238 { 55 nA in the presence of 10 mM dynorphin A(1-13) vs. 5 { 1 nA in the absence of dynorphin A(1-13); n Å 7, P õ 0.005, paired t-test]. Figure 3B shows the effect of glycine concentration on the amplitude of NMDA-activated current in the absence and presence of dynorphin A(1-13) (10 mM). The highest glycine concentration tested was 10 mM, which has been reported to be a maximal concentration for glycine potentiation of NMDAor glutamate-activated currents (Henderson et al. 1990 ). Assuming that 10 mM was also maximal for glycine potentiation of NMDA-activated current in the experiments reported here, dynorphin A(1-13) (10 mM) did not significantly alter the EC 50 values of the glycine concentration-response curves. The respective EC 50 values in the absence and presence of dynorphin A(1-13) (10 mM) were as follows: e1/ z1, 2.13 versus 1.51 mM; e2/z1, 1.32 versus 2.38 mM; e3/ z1, 2.13 versus 3.89 mM; and e4/z1, 0.54 versus 1.07 mM (P ú 0.05, ANOVA). Note also that in Fig. 3B the variability of current amplitude in the presence of dynorphin A(1-13) was relatively small, whereas in Fig. 3A the variability in percentage potentiation by dynorphin A(1-13) was quite large. This large variability was caused by a considerable difference between individual oocytes in the amplitude of NMDA-activated current at low glycine concentrations in the absence of dynorphin A(1-13). For example, in oocytes expressing e2/z1 subunits, NMDA-activated current in the 13) may have a glycinelike action on NMDA receptors. We therefore tested the effect of kynurenic acid, a competitive antagonist at the glycine coagonist site on NMDA receptors. Figure 5A illustrates representative current records of the potentiation of NMDA-activated current by 10 mM dynorphin A(1-13) and in the presence of 100 nM added glycine, and the inhibition of this potentiation by 50 mM kynurenic acid in an oocyte expressing the e4/z1 subunits. The bar graphs in Fig. 5B show the average data from five oocytes. Potentiation of NMDA-activated current by 10 mM dynorphin A(1-13), expressed as percentage of control, was 7,727 { 4,142%, and this potentiation was significantly inhibited to 1,561 { 1,385% in the presence of 50 mM kynurenic acid (P õ 0.005, paired t-test).
Effect of dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , (2-13), (3-13) , and (4-13) on NMDA-activated current at low glycine concentrations The first amino acid of the dynorphin A peptide, a tyroof NMDA-activated currents at added glycine concentrations indicated for sine, has been found to be essential for the k-opioid effects oocytes expressing e1/z1, e2/z1, e3/z1, or e4/z1 NMDA receptor subunits. Asterisks: significant potentiation [P õ 0.05, analysis of variance (ANOVA)]. B: glycine concentration-response curves for NMDA-activated currents in absence (᭺) and presence (q) of 10 mM dynorphin A(1-13) for oocytes expressing e1/z1, e2/z1, e3/z1, or e4/z1 NMDA receptor subunits. In A and B, each data point represents mean { SE for 6-12 oocytes. Error bars not visible are smaller than symbol. Curves shown are fitted to logistic equation given in METHODS .
Effect of k-opioid receptor agonist and antagonist on dynorphin A(1-13) potentiation of NMDA-activated current
Dynorphin A exerts many of its effects by interaction with k-opioid receptors. To determine whether the potentiation of NMDA receptor-mediated responses by dynorphin A(1-13) involves k-opioid receptors, we studied the effect of the k-opioid receptor agonist U50488 and the k-opioid receptor antagonist NorBN1. Figure 4A shows traces recorded from an individual oocyte in the presence of 100 nM added glycine, illustrating that there was little current when either NMDA, 10 mM U50488 alone, or 10 mM U50488 plus NMDA was applied. The current was greatly increased in amplitude when 10 mM dynorphin A(1-13) was applied with NMDA in the same oocyte. On average, in the presence of 100 nM added glycine, there was no significant difference between currents activated by NMDA, 10 mM U50488, or NMDA plus 10 mM U50488 ( Fig. 4B ; P ú 0.05, ANOVA). Figure 4C illustrates the effect of NorBN1 on NMDA-activated currents. In the presence of 100 nM added glycine, FIG . 4. Effects of k-opioid agonist and antagonist on NMDA-activated current and dynorphin A(1-13) potentiation of NMDA-activated current.
NMDA activated little current in the absence or presence of A: representative traces showing effect of k-opioid agonist trans-3,4-di-3 mM NorBN1. Dynorphin A(1-13) (10 mM), in contrast, chloro-N-methyl-N-[2-(1-pyrrolidinyl) -cyclohexyl]benzene-acetamide potentiated NMDA-activated current, and this potentiation (U50488, 10 mM) recorded from oocyte expressing e4/z1 NMDA receptor was not inhibited by 1 mM NorBN1. There was no significant subunits. From left to right, 1st trace shows control NMDA-activated current, 2nd trace shows that U50488 alone elicited no appreciable current, difference between the effect of NMDA in the absence or and 3rd trace shows that U50488 did not potentiate NMDA-activated curpresence of 3 mM NorBN1, or between the dynorphin A(1-rent, unlike 10 mM dynorphin A(1-13) (4th trace). B: bar graphs showing 13) potentiation of NMDA-activated current in the absence average (mean { SE) data relevant to traces in A (n Å 6) C: representative or presence of NorBN1 ( Fig. 4D; P t-test), but not for dynorphin A(4-13) (P ú 0.05, paired t-test). Dynorphin A(2-13) did not show a significantly greater potentiation of NMDA-activated current than dynorphin A(1-13) (P ú 0.05, paired t-test); however, the potentiation by dynorphin A(3-13) was significantly greater than that of either dynorphin A(1-13) or dynorphin A(2-13) (P õ 0.05, ANOVA). Dynorphin A(4-13) did not potentiate NMDA-activated current (P ú 0.05, unpaired t-test).
Effect of dynorphin A(1-13) and (2-13) on NMDAactivated current in hippocampal neurons at low glycine concentrations
To determine whether dynorphin can also potentiate NMDA receptors on neurons, we investigated the effect of dynorphin A(1-13) and dynorphin A(2-13) on NMDAmediated responses in hippocampal neurons at low extracellular glycine concentrations. Because the EC 50 for glycine is very low for NMDA-activated currents in neurons (150 nM) , the dynorphin experiments on hippocampal neurons were conducted in the absence of added glycine. Figure 7 shows that in the absence of added glycine, 10 mM dynorphin A(1-13) potentiated NMDAactivated currents by increasing the amplitude of the steadystate current. The observed potentiation of steady-state current, expressed as percentage of control, was 184 { 30% (n Å 7, P õ 0.05, paired t-test). In hippocampal neurons, FIG . 5. Effect of kynurenic acid on potentiation of NMDA-activated current by dynorphin A(1-13) in presence of 100 nM added glycine. A: representative traces from oocyte expressing e4/z1 NMDA receptor subunits of current activated by NMDA (left trace), NMDA plus 10 mM dynorphin A(1-13) (middle trace), and NMDA plus both 10 mM dynorphin A(1-13) and 50 mM kynurenic acid (right trace). B: bar graphs showing average (mean { SE, n Å 4) data relevant to traces in A.
of dynorphin A (Walker et al. 1982) . In addition, in the presence of high glycine concentrations, dynorphin A(1-17) has been found to inhibit NMDA receptor-mediated responses more potently than does dynorphin A(2-17) (Chen et al. 1995) . The second and third amino acids of the dynorphin A peptide are glycines. Because the potentiation of NMDA-activated current by dynorphin A(1-13) at low glycine concentrations appeared to be a glycinelike effect, we were interested to know whether the potentiation might involve either or both of these glycine residues. Figure  6 illustrates an experiment in which one or more of the first three amino acids were deleted from the dynorphin A(1-13) peptide to study this question. Figure 6A shows representative traces from one oocyte. At an extracellular added glycine concentration of 100 nM, the amplitude of NMDAactivated current was increased by 10 mM dynorphin A . Effects of dynorphin A(1-13), (2-13), (3-13), or (4-13) 13), (2-13), or (3-13); however, 10 mM dynorphin A(4-on NMDA-activated currents at low extracellular glycine concentrations.
A: representative current traces comparing effect of dynorphin A(1-13), 13), a peptide containing no glycine residue, did not increase (2-13), (3-13), or (4-13) (each 10 mM) on NMDA-activated currents the amplitude of NMDA-activated current. Figure 6B shows recorded from oocyte expressing e2/z1 NMDA receptor subunits. Note the average NMDA-activated current in these experiments. that each of dynorphins, with exception of dynorphin A(4-13), potentiated Potentiation of NMDA-activated current was significant for NMDA-activated current. B: bar graphs showing average (mean { SE) data relevant to traces in A (n Å 10).
dynorphin A(1-13), (2-13), or (3-13) (P õ 0.01, paired / 9k17$$au33 08-05-97 14:12:08 neupa LP-Neurophys nous k-opioid agonist (Caudle and Isaac 1988; Chavkin et al. 1982) , we tested whether the potentiation of NMDAactivated current by dynorphin A(1-13) is mediated by kopioid receptors. We found that the application of the kopioid agonist U50488 (10 mM) did not activate detectable current, nor did it affect the current activated by NMDA. Moreover, the opioid k-receptor antagonist NorBN1 (1 mM) did not affect NMDA-activated current, nor did it alter the potentiation of NMDA-activated current by dynorphin A(1-13). These observations suggest that the dynorphin A(1-13) potentiation of NMDA-activated current does not involve k-opioid receptors. In addition, the observation that dynorphin A(2-13) potentiated NMDA-activated current to an extent similar to the potentiation by dynorphin A(1-13) for both recombinant and native hippocampal NMDA receptors supports the interpretation that the dynorphin potentiation of NMDA-activated current does not involve kopioid receptors, because the first amino acid of the dynorphin peptide, tyrosine, has been found to be essential for the k-opioid effect of dynorphin A (Walker et al. 1982) . this, the observation that at low extracellular glycine concentrations NMDA can activate significant NMDA receptor-10 mM dynorphin A(2-13) also potentiated steady-state mediated current in the presence of dynorphin A(1-13) is NMDA-activated current (227 { 37%, n Å 6, P õ 0.0005, quite remarkable. In regard to this action of dynorphin A(1-paired t-test). There was no significant difference between 13), the potentiation of NMDA-activated current by dynorthe potentiation by dynorphin A(2-13) and that by dynor-phin A(1-13) was concentration dependent between 0.1 phin A(1-13) (P ú 0.05, ANOVA). and 10 mM dynorphin A(1-13), with an EC 50 value of 2.77 mM (Fig. 2 ). This compares with the glycine concentrationMeasurement of free glycine in experimental solutions response curves, which were also concentration dependent between 0.1 and 10 mM, with EC 50 values of 0.54-2.13 mM To address the possibility that the observed potentiation of (Fig. 3B) . The similarity between the dynorphin A(1-13) NMDA responses by dynorphin at low extracellular glycine and the glycine potentiation of NMDA-activated current sugconcentrations might be due to contamination of the experigests that dynorphin A(1-13) has a glycinelike action on mental solutions by glycine, we measured the concentration NMDA receptors. of free glycine in various solutions used in these experiBecause glycine is the second and third amino acid in the ments. The bathing solution was found to have a free glycine dynorphin A peptide, it was important to determine whether concentration of 26 { 4 nM (n Å 5). Solutions containing the glycinelike effect of dynorphin A(1-13) was due to a 10 mM of the various dynorphin peptides had the following glycine contamination of the dynorphin solutions. We therefree glycine concentrations: dynorphin A(1-13), 30 { 8 fore used HPLC to measure the free glycine concentration nM (n Å 4); dynorphin A(2-13), 31 { 4 nM (n Å 4); in the bathing solution in the absence and presence of dynordynorphin A(3-13), 27 { 6 nM (n Å 4); and dynorphin phin A(1-13), (2-13), (3-13), or (4-13). The observa-A(4-13), 36 { 7 nM (n Å 4). The free glycine concentration that the free glycine concentration in these solutions was tions of the bathing solution, and the bathing solution conbetween 26 and 36 nM, and that there were no significant taining any of these dynorphin peptides, were not signifidifferences among these free glycine concentrations, indicantly different (P ú 0.05, ANOVA).
cates that glycine contamination does not explain the glycinelike action of dynorphin A(1-13), (2-13), and (3-D I S C U S S I O N 13), because the dynorphin-free bathing solution and dynorphin A(4-13) had similar free glycine concentrations but The observations reported here show that, in the presence of low extracellular glycine concentrations, dynorphin A(1-did not exhibit a glycinelike action on NMDA-activated currents. 13) can increase the amplitude of NMDA-activated current for both recombinant NMDA receptors expressed in XenoBecause the biologically active part of the endogenous dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) consists of the first 13 amino acids, our pus oocytes and native NMDA receptors on hippocampal neurons. The endogenously occurring dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) , findings with the synthetic, truncated dynorphin A(1-13), (2-13), (3-13), and (4-13) may be extrapolated to the (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , and (1-32) also potentiated NMDA-activated current in Xenopus oocytes. Because dynorphin A is an endoge-endogenous dynorphin. Our observation that dynorphin A(1-13), (2-13), and (3-13) show potentiation of logical regulator of NMDA receptor function in the nervous system. NMDA-activated current and dynorphin A(4-13) does not may have implications for the physiological function of dyWe thank Dr. Masyoshi Mishina for providing NMDA receptor subunit norphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and the biotransformation of this peptide. 
